Published on 20 October 2022
Cheshire and Merseyside’s specialist cancer centre has enhanced its status as a world-class venue for research into the disease after becoming a partner in a Biomedical Research Centre (BRC).
BRC status comes after a collaboration was agreed between The Clatterbridge Cancer Centre and London’s Royal Marsden Hospital, which will see two leading research hospitals working together on turning ground-breaking clinical trials into fully-fledged treatments to further improve outcomes for patients.
Being a partner in a BRC is the latest sought-after accreditation for Clatterbridge, after it became a Clinical Research Facility (CRF) earlier this year and continues to be part of the Liverpool Experimental Cancer Medicine Centre (ECMC).
Clatterbridge’s Medical Director Dr Sheena Khanduri said: “We are delighted that The Clatterbridge Cancer Centre now becomes a partner in a Biomedical Research Centre in a forward-looking collaboration with The Royal Marsden. We will be working with our colleagues in London on many important areas of research.
“Being in a BRC enhances our ability to lead extra and more complex clinical research trials to extend Clatterbridge’s reputation as a leading centre for cutting-edge cancer research globally. It also gives our patients even more access to pioneering research and ground-breaking therapies that will benefit them directly.”